Early toxicity and clinical outcomes after chimeric antigen receptor T-cell (CAR-T) therapy for lymphoma.

Jonathan E BrammerZachary BraunsteinAashish KatapadiKyle PorterMichael BiersmithAvirup GuhaSumithira VasuVedat O YildizSakima A SmithBenjamin BuckDevin HaddadRichard GuminaBasem M WilliamSam PenzaAyman SaadNathan DenlingerAjay VallakatiRagavendra BaligaRaymond BenzaPhilip BinkleyLai WeiMason MocarskiSteven M DevineSamantha JaglowskiDaniel Addison

Published in: Journal for immunotherapy of cancer (2022)

Among adult lymphoma patients, moderate toxicity manifest as grade 2 CRS after CAR-T infusion may associate with favorable clinical outcomes. Further studies are needed to confirm these findings.

Keyphrases

end stage renal disease
diffuse large b cell lymphoma
ejection fraction
oxidative stress
chronic kidney disease
newly diagnosed
prognostic factors
high intensity
young adults
patient reported outcomes